



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/22	A1	(11) International Publication Number: WO 98/35696 (43) International Publication Date: 20 August 1998 (20.08.98)
(21) International Application Number: PCT/US98/02830 (22) International Filing Date: 17 February 1998 (17.02.98) (30) Priority Data: 08/801,480 18 February 1997 (18.02.97) US (71) Applicant: SCICLONE PHARMACEUTICALS, INC. [US/US]; 901 Mariner's Island Boulevard, San Mateo, CA 94404 (US). (72) Inventor: KNUTSEN, Alan, P.; 234 W. Jackson, St. Louis, MO 63119 (US). (74) Agents: REPPER, George, R. et al.; Rothwell, Figg, Ernst & Kurz, Suite 701 East, 555 13th Street, N.W., Washington, DC 20004 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: USE OF THYMOSIN ALPHA 1 FOR THE MANUFACTURE OF A MEDICAMENT FOR PROMOTING STEM CELL DEVELOPMENT		
(57) Abstract A method of promoting stem cell development in a mammal in need of stem cell development includes administering to the mammal a stem cell development enhancing effective amount of Thymosin α_1 ($T\alpha_1$).		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF THYMOSIN ALPHA 1 FOR THE MANUFACTURE OF A MEDICAMENT FOR PROMOTING STEM CELL DEVELOPMENT

Field of the Invention

5 The present invention relates generally to a method of promoting stem cell development.

Background of the Invention

Both B lymphocytes ("B cells") and T lymphocytes ("T cells") play important roles in mammalian immune systems. B cells control humoral immunity through antibody production. T cells account for nearly all forms of cellular immunity.

10

T cells originate in the thymus. Generally, thymic stem cells which are derived from precursor cells originating in bone marrow develop into blast cells which, in turn, develop into a variety of mature T cells. The developmental process from stem cell to mature T cell is referred to as stem cell differentiation or thymopoiesis. The developmental process from bone marrow precursor cell to mature T cell is referred to as T cell development. Stem cell development may include stem cell proliferation and differentiation into T cells. If stem cell differentiation progresses slowly or incompletely or if there is a shortage of stem cells in the thymus, a deficiency of T cells can result.

15

20

25

Thus, a T cell deficiency can result from a number of different factors. For example, T cell deficiencies exist in immunodeficient humans, such as individuals infected with HIV. In humans infected with HIV, it is
5 believed that such deficiencies result not only from the virus attacking and killing T cells (e.g., CD4 cells) but also from a decrease in stem cell differentiation in the infected humans due to a change in the thymic milieu caused by the overall HIV
10 infection. Moreover, T cell deficiencies exist in humans having a shortage of stem cells, such as individuals in need of a bone marrow transplant.

Thymosin Fraction Five (TF-5), originally described by Goldstein et al. (Proc. Nat'l Acad. Sci. (USA), 69:1800-1803 (1972)), is a partially purified
15 extract of bovine thymus containing at least 40 peptide components, 20 of which have been purified to homogeneity or near homogeneity; it contains about 0.6% of Thymosin α_1 ($T\alpha_1$). Low, T.L.K., et al., "Thymosins: Structure, Function and Therapeutic Application",
20 Thymus, 6:27-42 (1984).

Thymosin α_1 (" $T\alpha_1$ ") is a peptide originally derived from the thymus gland, which has been reported as containing 28 amino acids. Amino acid sequence
25 information on $T\alpha_1$ is disclosed in U.S. Patent No. 4,079,127.

$T\alpha_1$ is an immune system modulator which heretofore has been reported as being useful, inter alia, in the treatment of lung cancer, Hepatitis B and Hepatitis C.
30 Moreover, it previously has been suggested that $T\alpha_1$ might induce the expression of certain T cell markers as well as functional activity associated with lymphocyte maturation such as helper T cell activity, specific antibody production and production of

macrophage inhibiting factor. Low, 1984, supra, at page 33.

5 A T cell deficiency as described above can have devastating and sometimes fatal effects on those afflicted with this condition, as is evident from recent experience with AIDS. Clearly, there is a need in the art for new and effective methods of promoting development in humans who are T cell deficient. Accordingly, there is a need in the art for new and effective methods of promoting stem cell development in those individuals in need of such development.

Summary of the Invention

15 In accordance with the present invention, a method of promoting stem development in a mammal in need of stem cell development includes administering to said mammal a stem cell development enhancing effective amount of Thymosin α_1 .

20 Also in accordance with the present invention, a method of promoting T cell differentiation from stem cells in a mammal in need of T cell differentiation includes administering to said mammal a T cell differentiation effective amount of Thymosin α_1 .

Brief Description of the Drawings

25 Fig. 1 is a schematic diagram depicting the *in vitro* coculture model of thymopoiesis utilized in Example 3.

Fig. 2 is a graph depicting the results of purifying CD34+ stem cells from bone marrow. These results show that >99% of the stem cells utilized in

the *in vitro* coculture model of thymopoiesis expressed CD34+.

Fig. 3 depicts flow cytometry results which show the effect which $T\alpha_1$ had on the cell number per well as a function of time in the *in vitro* stem cell-cultured thymic epithelial fragment (SC-CTEF) coculture model of thymopoiesis illustrated in Fig. 1.

Fig. 4 depicts flow cytometry results which show the effect $T\alpha_1$ had on the expression of CD25+ as a function of time in the *in vitro* SC-CTEF coculture model of thymopoiesis illustrated in Fig. 1.

Fig. 5 depicts flow cytometry results which show the effect $T\alpha_1$ had on the expression of CD44+25+ as a function of time in the *in vitro* SC-CTEF coculture model of thymopoiesis illustrated in Fig. 1.

Fig. 6 depicts flow cytometry results which show the effect $T\alpha_1$ had on the expression of CD44+25+3- as a function of time in the *in vitro* SC-CTEF coculture model of thymopoiesis illustrated in Fig. 1.

Fig. 7 depicts flow cytometry results which show the effect $T\alpha_1$ had on the expression of single positive CD4+ (spCD4+) as a function of time in the *in vitro* coculture model of thymopoiesis illustrated in Fig. 1.

Description of the Preferred Embodiments

It surprisingly has been discovered that Thymosin α_1 ($T\alpha_1$) is particularly and unexpectedly effective in promoting stem cell development. This is particularly advantageous for mammals in need of such development.

The terms "Thymosin α_1 " and " $T\alpha_1$ " refer to peptides having the amino acid sequence disclosed in U.S. Patent No. 4,079,127, the disclosure of which is incorporated herein by reference.

5 According to the present invention, methods of promoting stem cell development and T cell differentiation from stem cells are provided. The methods of the present invention include administering to the mammal a stem cell development enhancing
10 effective amount of $T\alpha_1$.

 According to preferred embodiments of the present invention, effective amounts of $T\alpha_1$ are administered to mammals in need of stem cell development to promote stem cell development in the mammals. The amount of $T\alpha_1$
15 administered to the mammals to promote stem cell development is preferably between about 0.1 μg $T\alpha_1$ per kg body weight of the mammal and about 4 μg $T\alpha_1$ per kg body weight and, more preferably, between about 5 μg $T\alpha_1$ per kg body weight (i.e., about 0.5 mg $T\alpha_1$) and about
20 65 μg $T\alpha_1$ per kg body weight (i.e., about 5 mg $T\alpha_1$). In a most preferred embodiment of this invention, about 20 μg $T\alpha_1$ per kg body weight (i.e., about 1.6 mg $T\alpha_1$) is administered to the mammals in need of stem cell development. Actual dosages administered can be in the
25 range of about 0.1-10 mg, about 0.5 - 5 mg or about 1-2 mg, with a dosage of 1.6 mg being contemplated. In these embodiments, the mammals preferably are human.

 According to one aspect of the present invention, the mammals to which $T\alpha_1$ is administered are in need of
30 stem cell development. Mammals in need of stem cell development may include, but are not limited to, mammals that are T cell- and/or stem cell-deficient.

$T\alpha_1$ may also promote stem cell proliferation. Mammals afflicted with an immunodeficiency disease (e.g., humans who have AIDS or are HIV positive) and animals in need of a bone marrow transplant are generally in need of stem development. According to another aspect of the present invention, $T\alpha_1$ can be administered to mammals in need of stem cell development on a routine basis. For example, $T\alpha_1$ can be administered daily, twice a day, three times a day, every other day, weekly, monthly, etc. The frequency of administration, of course, will depend upon the quantity and formulation of $T\alpha_1$ being administered.

According to the preferred embodiments of the present invention, compositions containing $T\alpha_1$ may be formulated in a conventional manner for administration by any suitable route. Suitable routes of administration include, but are not limited to, oral, rectal, nasal, topical, vaginal, and parenteral (including subcutaneous, intramuscular, intravenous and intradermal). Particularly preferred embodiments utilize oral or parenteral administration, with parenteral administration being a more preferred embodiment. It will be appreciated that the preferred route may vary with the condition, age and species of the recipient.

While not essential, in preferred embodiments, $T\alpha_1$ is administered as part of a pharmaceutical formulation. The formulations of the present invention comprise $T\alpha_1$ together with one or more pharmaceutically acceptable carriers and optionally with other therapeutic ingredients. The carrier(s) are "acceptable" in the sense of being compatible with the

other ingredients of the formulation and not deleterious to the recipient thereof.

5 The formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and may be prepared by any suitable pharmaceutical methods.

10 Such methods include, but are not limited to, the step of bringing into association $T\alpha_1$ with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association $T\alpha_1$ with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

15 Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of $T\alpha_1$; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, etc.

25 A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine $T\alpha_1$ in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be

formulated so as to provide slow or controlled release of the active ingredient therein.

Formulations suitable for topical administration include lozenges comprising $T\alpha_1$ in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising $T\alpha_1$ in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising $T\alpha_1$ to be administered in a suitable liquid carrier.

Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising $T\alpha_1$ and a pharmaceutically acceptable carrier, or may utilize a transdermal patch containing the ingredient to be administered.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size, for example, in the range from about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.

Formulations suitable for vaginal administration may be presented as tampons, creams, gels, pastes, foams or spray formulations containing, in addition to $T\alpha_1$, suitable carriers.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile

injection solutions which may optionally contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other suitable agents having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.

The present invention is applicable to native (i.e., naturally occurring) $T\alpha_1$, as well as synthetic $T\alpha_1$ and recombinant $T\alpha_1$ having the amino acid sequence of native $T\alpha_1$, amino acid sequences substantially similar thereto, or an abbreviated sequence form thereof, and their biologically active analogs (including muteins) having substituted, deleted, elongated, replaced, or otherwise modified sequences which possess bioactivity substantially similar to that of $T\alpha_1$.

The following examples are for illustrative purposes only, and are not to be construed in a limiting sense.

ExamplesEXAMPLE 1Preparation of Injectable Formulation

Pharmaceutical dosage units of 1 ml each are
5 prepared from the ingredients shown in Table 1 below.

TABLE 1

	<u>Active Ingredient</u>	<u>Amount Per mL</u>
	Thymosin α -1	0.0064 g
	<u>Inactive Ingredients</u>	
10	mannitol, U.S.P.	0.050 g
	sodium phosphate dibasic, heptahydrate, U.S.P.	0.002 g
	sodium phosphate monobasic, monohydrate, U.S.P.	0.0005 g
15	sodium phosphate dibasic, 2 mg/ml solution	
	sodium phosphate monobasic, 0.5 mg/ml solution	
	water for injection, U.S.P.	
20	<hr/>	

EXAMPLE 2Preparation of Injectable Formulation

Pharmaceutical dosage units of 1 ml each are prepared from the ingredients shown in Table 2 below.

5

TABLE 2

	<u>Active Ingredient</u>	<u>Amount Per mL</u>
	Thymosin α -1	0.0032 g
	<u>Inactive Ingredients</u>	
	mannitol, U.S.P.	0.050 g
10	sodium phosphate dibasic, heptahydrate, U.S.P.	0.002 g
	sodium phosphate monobasic, monohydrate, U.S.P.	0.0005 g
15	sodium phosphate dibasic, 2 mg/ml solution	
	sodium phosphate monobasic, 0.5 mg/ml solution	
	water for injection, U.S.P.	

EXAMPLE 3**Effects of Thymosin- α_1 on CD34+ Stem Cell
Differentiation in Cultured Thymic Epithelia in vitro****Material and Methods**

5 To evaluate the effect of T α_1 on thymopoiesis, an
in vitro coculture model of thymopoiesis was utilized.
In this model, as set forth in Figure 1, CD34+ stem
cells were isolated from bone marrow by positive
selection using CD34+ antibody coated beads and
10 immunomagnetic selection, MiniMACS (Miltenyi). As
illustrated in Figure 2, the separation procedure was
extremely efficient with >99% of the stem cells
expressing CD34+. CD34+ stem cells were a
heterogeneous population. Thus, in some experiments,
15 more immature CD34+ population was used, depleted of
CD2+CD4+ cells.

Thymus tissue was obtained from children less than
2 years of age undergoing cardiac surgery. The thymic
tissue was minced into 1 mm³ fragments and cultured in
20 1.35 mM 2-deoxyguanosine for 10-14 days in order to
deplete the thymic tissue of thymocytes in a 5% CO₂
humidified atmosphere. The thymic fragments were then
cultured in growth media (Iscove's/Ham's F-12 media
supplemented with 5% FCS and epidermal growth factor).

25 Subsequently, CD34+ stem cells were cocultured
with the cultured thymic epithelia fragments in 24-well
transwell culture plates in Iscove's/Ham's F-12 media
supplemented with 5% FCS, epidermal growth factor and
IL-2 in a 5% CO₂ humidified atmosphere. Approximately
30 100,000 CD34+ stem cells were cocultured with 3-5
thymic fragments. 10 μ g/ml of T α_1 was added to parallel

cocultures. Media and $T\alpha_1$ of cocultures were replaced twice weekly.

At weekly intervals, cultures were harvested to analyze thymocyte subpopulations by flow cytometry.

5 T cell surface phenotypes of the differentiated stem cells were determined by reacting monoclonal antibodies (mAb) conjugated with either fluorescein (FITC), phycoerythrin (PR), and peridinin chlorophyll protein (Per-CP) and were then analyzed by flow cytometry.

10 Monoclonal antibodies used are listed in Table 3 below. Combinations of mAbs were used to identify immature thymocytes, such as double-positive (CD3-CD4+CD8+) and triple positive (CD3+CD4+CD8+) thymocytes, and mature CD3+C4+CD8- and CD3+CD4+CD8+ T cells. Analysis of
15 thymocyte subpopulations was performed using WinList software.

Results

Initially, a dose response of $T\alpha_1$ was performed ranging from 1 to 10 $\mu\text{g/ml}$. Optimal effects were
20 observed at 10 $\mu\text{g/ml}$ which then was used in subsequent experiments. As shown in Figure 3, $T\alpha_1$ increased the proliferation of cocultured cells harvested at all time points from the cocultures compared to media alone. Increased proliferation or expansion of thymocytes
25 stimulated by $T\alpha_1$ paralleled media alone with peak proliferation observed at 3 weeks, 16.6 versus 10.4 fold increase.

Thymocyte subpopulations were then analyzed to determine whether $T\alpha_1$ affected thymocyte maturation. As
30 illustrated in Figure 4, $T\alpha_1$ significantly increased thymocyte CD25+ expression at 1, 3 and 4 weeks of coculture. $T\alpha_1$ significantly stimulated CD25+

expression at 1 week, 40% versus 23%, and was significantly increased at 4 weeks, 56% versus 31%.

CD44 and CD25 expression were also evaluated in this model system since CD44 expression appears early
5 in differentiation in the subcapsular cortex prior to expression of TCR, CD3, CD4 and CD8, i.e. triple negative thymocytes. Other groups have reported that CD44 plays an important role in thymocyte migration and maturation. As thymocytes further mature through
10 double and triple positive thymocyte stages, CD44 disappears but then reappears in more mature thymocytes. The ligands for CD44 include hyaluronate and fibronectin, matrix proteins which promote cell adhesion. In this model of stem cell differentiation,
15 $T\alpha_1$ significantly increased CD44+CD25+ expression in the first three weeks of coculture, peaking at 3 weeks 46% versus 30%. See Figure 5. Furthermore, $T\alpha_1$ increased early thymocyte maturation by increased expression of CD44+25+3- thymocytes at 1 week, 12% versus 7%. See
20 Figure 6. Though $T\alpha_1$ did not affect CD3, CD4 CD8 expression, it did increase mature single positive CD3+4+ expression at 3 weeks, 31% versus 23%. Other thymocyte surface phenotypes, such as TCR, CD2, CD7, CD45RA and CD45RO, were not affected by $T\alpha_1$.

25 Thus, $T\alpha_1$ dramatically increased CD25 expression throughout the coculture period. It stimulated expression of an early thymocyte, CD44+25+3- pre-T cell, at 1 week of coculture. As thymocytes matured, expression of this thymocyte stage waned similar to
30 control cocultures. $T\alpha_1$ also promoted expression of mature single positive CD4+ T cells at 3 weeks of coculture. Throughout the coculture period, $T\alpha_1$ stimulated proliferation of thymocytes. From these

studies it is clear that $T\alpha_1$ promotes T cell differentiation from stem cells.

TABLE 3

Monoclonal antibodies

mAb	Clone	Specificity
		<i>Mononuclear Cells</i>
CD7	Leu9	Prethymic Precursor T cell
CD33	LeuM9	Progenitors, monocytes; related to myelin-associated glycoprotein
CD34	HPCA-2	Bone marrow progenitor cell
CD38	Leu17	Progenitors; growth-factor receptor
CD44	Leu44	Progenitor cell committed to thymocytes and thymic dendritic cells
CD2	Leu5b	T and NK cells; cytoadhesion molecule binding LFA-3
CD3	Leu4	Multichain receptor associated with TCR
CD4	Leu3a	T helper/inducer; cytoadhesion glycoprotein binds to MHC II
CD8	Leu2a	T cytotoxic/suppressor; cytoadhesion glycoprotein binds to MHC I
TCR $\alpha\beta$	WT31	T cell receptor α/β chains
TCR $\gamma\delta$	11F2	T cell receptor γ/δ chains
CD25	2A3	Low affinity IL-2 α chain receptor
CD69	Leu23	B- and T cells; activation-inducer
CD45RA	Leu18	Isoform of CD45; naive cell
CD45RO	UCHL-1	Isoform of CD45; memory cell
CD14	LeuM3	Monocytes, dendritic cells
CD49d	HP2.1	VLA- α 4 integrin chain, fibronectin receptor
CD49e	SAM1	VLA- α 5 integrin chain, fibronectin receptor
CD11a	25.3	LFA-1 integrin α L chain
CD18	7E4	Integrin β 2 chain
CD29	K20	Integrin β 1 chain
CD16	Leu11c	Natural killer, granulocytes; Fc γ RIII
CD56	Leu19	Isoform of N-CAM; NK and T cytotoxic subset
CD20	Leu16	B cells
HLA-DR	DR	HLA cells class II molecules

mAb	Clone	Specificity
		<i>Thymic Epithelia</i>
TE3	7B12	Cortical thymic epithelium and fibroblast
TE4	TE4	Medullary and subcapsular cortical thymic endocrine epithelium
CDR2		pan epithelia
		<i>HIV</i>
p24	26C	HIV-1 p24, cytoplasmic
Protease	H2930	HIV-1 protease

EXAMPLE 4**Treatment of Adults in Need of Stem Cell****Differentiation With $T\alpha_1$**

Adult patients in need of stem cell differentiation are selected (e.g., adults with a T cell count of less than 200).

Each patient receives $T\alpha_1$ at a dose of 1.6 mg subcutaneously (SQ) every other day.

Outpatient following is initially at one-week intervals for two weeks, then at two-week intervals for two months, and then monthly for the remainder of the treatment period. At each visit the T cell count is monitored.

Drug toxicity is monitored on an ongoing basis using both clinical and laboratory parameters.

While the invention has been described and illustrated with details and references to certain preferred embodiments, those skilled in the art will appreciate that various modifications, changes,


omissions, and substitutions can be made without departing from the spirit of the invention.

What is claimed is:

1. A method of promoting stem cell development in a mammal in need of stem cell development which comprises administering to said mammal a stem cell development enhancing effective amount of Thymosin α_1 ($T\alpha_1$).
5
2. The method of claim 1, wherein said mammal is HIV positive.
3. The method of claim 1, wherein said mammal is in need of a bone marrow transplant.
10
4. The method of claim 1, wherein the amount of $T\alpha_1$ administered to said mammal is between about 0.1 μg $T\alpha_1$ per kg body weight of the mammal and about 4.0 μg $T\alpha_1$ per kg body weight.
- 15 5. The method of claim 4, wherein the amount of $T\alpha_1$ administered to said mammal is between about 5 μg $T\alpha_1$ per kg body weight of the mammal and about 65 μg $T\alpha_1$ per kg body weight.
6. The method of claim 5, wherein the amount of $T\alpha_1$ administered to said mammal is about 20 μg $T\alpha_1$ per kg body weight of the mammal.
20
7. The method of claim 1, wherein said mammal is human.
8. The method of claim 1, comprising promoting T cell differentiation from said stem cells.
25
9. The method of claim 1, wherein said amount is a dosage of about 0.1-10 mg.
10. The method of claim 1, wherein said amount is a dosage of about 0.5-5 mg.
- 30 11. The method of claim 1, wherein said amount is a dosage of about 1-2 mg.


12. The method of claim 1, wherein said amount is a dosage of about 1.6 mg.

FIG. 1




2 / 7

FIG. 2




3 / 7

FIG. 3




4 / 7

FIG. 4




5 / 7

FIG. 5




6 / 7

FIG. 6



7 / 7

FIG. 7



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/02830

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YUMIKO OHTA ET AL.: "Immunomodulating activity of thymosin fraction 5 and thymosin alpha 1 in immunosuppressed mice" CANCER IMMUNOL. IMMUNOTHER., vol. 15, no. 2, 1983, pages 108-113, XP002063754	1
Y	see abstract	2-12
X	YUMIKO OHTA ET AL.: "Thymosin alpha 1 enhances haematopoietic colony formation by stimulating the production of interleukin 3 in nu/nu mice" INT.J.IMMUNOPHARMACOL., vol. 8, no. 7, 1986, pages 773-779, XP002063755	1
Y	see abstract see page 777 - page 778	2-12
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

29 April 1998

Date of mailing of the international search report

22 05.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 551 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Tzschoppe, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/02830

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 079 127 A (ALLAN L. GOLDSTEIN ET AL.) 14 March 1978 cited in the application see column 1	1-12
Y	--- CHEMICAL ABSTRACTS, vol. 92, no. 3, 21 January 1980 Columbus, Ohio, US; abstract no. 16153, KHAITOV ET AL.: "Factors controlling hematopoietic stem cell recirculation. IV. Effect of thymosin on the migration and differentiation of hematopoietic stem cells" XP002063757 see abstract & TSITOLOGIYA, vol. 21, no. 9, 1979, pages 1058-1064,	1-12
X	--- CHEMICAL ABSTRACTS, vol. 114, no. 25, 24 June 1991 Columbus, Ohio, US; abstract no. 241049, KONDO, KAORU: "Effects of thymic humoral factors on hematopoietic stem cells in human" XP002063758	1
Y	see abstract & NAGOYA-SHIRITSU DAIGAKU IGAKKAI ZASSHI, vol. 41, no. 3, 1990, pages 467-482,	2-12
P,X	--- AP KNUTSEN ET AL.: "In vitro effect of thymosin-alpha 1 on stem cell differentiation in cultured thymic epithelia" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1 part 1, January 1997, page s131 XP002063756 see abstract -----	1,8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/02830

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4079127 A	14-03-1978	AR 214903 A	15-08-1979
		AT 362493 B	25-05-1981
		AU 514996 B	12-03-1981
		AU 2969977 A	26-04-1979
		BE 860169 A	27-04-1978
		CA 1101842 A	26-05-1981
		CH 633258 A	30-11-1982
		DE 2748213 A	11-05-1978
		DK 478277 A,B,	29-04-1978
		FI 773221 A,B,	29-04-1978
		FR 2369248 A	26-05-1978
		GB 1590457 A	03-06-1981
		JP 1345074 C	29-10-1986
		JP 54011220 A	27-01-1979
		JP 61008805 B	18-03-1986
		LU 78395 A	02-02-1979
		NL 7711814 A,B,	03-05-1978
		PT 67204 B	12-11-1979
		SE 442479 B	13-01-1986
		SE 7712071 A	29-04-1978
		SG 122093 G	10-06-1994
		ZA 7705976 A	28-06-1978